Retatrutide vs tirzepatide
Two molecules from the same family separated by one receptor. What actually sets them apart, and what cannot be claimed yet.
Before the comparison
Both compounds are distributed here, when they are in the catalog, as research reagents: laboratory material with no approved indication, not intended for human use. Approved medicines built on some of these molecules do exist, and every piece of clinical evidence cited on this page belongs to those medicines, not to the vial.
The difference in one sentence
Tirzepatide activates two receptors; retatrutide, three. That is the heart of the matter and everything else follows from it. Both are peptides of 39 amino acids with related structures, both born of the same line of research into the incretin-glucagon system.
Tirzepatide is a dual GIP / GLP-1 agonist. Retatrutide adds the receptor for glucagón and becomes a triple agonist. GLP-1 and GIP are incretins — gut hormones involved in satiety signaling and glucose metabolism — while glucagon acts on hepatic glucose and, in the literature, is also studied in relation to energy expenditure. Adding the third axis is the hypothesis retatrutide is being tested to verify.
Comparison table
| Criterio | Retatrutide | Tirzepatide |
|---|---|---|
| Receptors it acts on | Three: GIP, GLP-1 and glucagon (triple agonist) | Two: GIP and GLP-1 (dual agonist) |
| Chain length | 39 amino acids | 39 amino acids |
| Regulatory status | Not approved in any country; still in clinical investigation | Approved as a medicine in several countries, under a brand name and by prescription |
| Published trials | Phase III program ongoing; available data come from earlier phases | Phase III programs completed and published |
| Frequency studied | Weekly, according to phase I pharmacokinetic studies | Weekly; half-life on the order of five days |
| In the amino catalog | Yes, as a research reagent, in a lyophilized vial | Yes, as a research reagent, in a lyophilized vial |
The difference that weighs most: regulatory status
It is the one almost nobody mentions and the one that changes the picture most. Tirzepatide has marketing authorization in several countries: it is sold under a brand name, requires a medical prescription and is backed by a complete clinical program with a summary of product characteristics. Retatrutide is not approved in any country: it remains inside its clinical research program.
That means that for tirzepatide there is a body of evidence with a name attached — that of the medicine, in its indication, at its doses and under supervision. For retatrutide that body of evidence is still being built. And in neither case does that evidence transfer to a laboratory vial, which is a different category of product: defined by its certificate of analysis, not by a marketing authorization.
What cannot be claimed
That one is more effective than the other. Sustaining that sentence requires direct comparative trials and a completed phase III program, and retatrutide has neither. The sites in this sector publishing tables of “how many kilos with each one” are extrapolating from separate studies with different populations and durations — an exercise the literature does not permit, and one that also ignores that we are talking about reagents, not treatments.
Retatrutide in the catalog
Ten lyophilized vial sizes, from 5 to 100 mg, with HPLC-verified purity and a batch certificate of analysis. The price per milligram falls as the size goes up: $1,599 – $5,949 MXN.
FAQ
What is the difference between retatrutide and tirzepatide?
The glucagon receptor. Tirzepatide acts on two receptors of the incretin system, GIP and GLP-1; retatrutide adds a third, that of glucagon, which is why it is described as a triple agonist. Both are 39-amino-acid peptides with related structures, but that third receptor is what separates one molecule from the other.
Which one is better?
That is not a question amino can answer, and it is worth explaining why rather than dodging it. Comparing efficacy requires direct comparative clinical trials, and retatrutide has not even finished its phase III program. Beyond that, the evidence that does exist belongs to the approved medicines and their supervised context of use, not to the laboratory material distributed here. Any supplier who tells you which is better is selling you a conclusion the literature does not yet have.
Which compounds from this family are in the catalog?
La familia incretínica está representada por la retatrutida, la tirzepatida, la semaglutida, la liraglutida y la cagrilintida, además del vial que combina retatrutida con cagrilintida. All share the same standard: ≥99% purity verified by HPLC and a batch certificate of analysis.: pureza verificada por HPLC y certificate of analysis por lote.
What does it mean that retatrutide is a triple agonist?
That it binds three receptors instead of one or two. GLP-1 and GIP are incretins: gut hormones involved in satiety signaling and glucose metabolism. Glucagon acts in the opposite direction on hepatic glucose and, in the research literature, is also associated with energy expenditure. Combining all three in a single molecule is precisely the hypothesis the compound is being tested to verify.
Broader context on the family in the guide to peptides and weight, and batch verification on the certificates page.
amino makes no claims of efficacy or safety in humans. The information on this page summarizes research literature for technical reference and does not constitute medical advice, an indication of use, or a dosing suggestion. All compounds are research-grade reagents (RUO) for laboratory use only.